A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy.

Trial Profile

A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Ixabepilone (Primary) ; Doxorubicin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms IXAMPLE2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Mar 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.
    • 12 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 27 Aug 2013 Planned end date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top